Brief Introduction

Allgens Medical Technology CO., LTD.was founded in 2004, and is a national high-tech enterprise focusing on the technology research and development, high-end manufacturing and market promotion of advanced biomaterials and implantable medical devices for regenerative medicine.

Allgens biomimetic mineralized collagen bone grafts have three national class III medical device registration certificates approved by NMPA, and have been approved by US FDA 510(k). With similar composition and microstructure to those of human bone, the products can be widely used for bone grafting in the fields of orthopedics, neurosurgery, stomatology, plastic surgery, and so on. The products have been used in more than one million cases, with remarkable bone defect repair and bone fusion effects. Many patients and their families obtained benefits from Allgens techniques and products.

Company Overview

Full name Allgens Medical Technology CO., LTD.
Abbreviations Allgens
Code 688613
Founded 2004-12-22
Listing 2021-5-21
Domicile Beijing
STAR Theme Biomedicine
CSRC Sector Manufacturing
Has weighted voting rights structure? No



  2020 2019 2018
Earnings Per Share 0.89 0.68 0.34
R&D expenditure as a % of operating revenue 8.71% 13.34% 14.57%
Operating Revenue 183.76 168.59 123.69
Net Income 87.12 64.2 27.5

Income Statement (Unit: RMB mn)

  2020 2019 2018
Operating Revenue 183.76 168.59 123.69
Operating Costs 89.48 107.31 96.26
Operating Income 102.19 74.45 34.8
Pretax Income 102.08 74.55 34.25
Income Tax 14.96 10.36 6.74
Net Income 87.12 64.2 27.5

Balance Sheet(Unit: RMB mn)

  2020 2019 2018
Current Assets-Total 554.48 489.44 370.97
Non-current Assets-Total 250.45 226.64 154.13
Total Assets 804.93 716.08 525.1
Current Liabilities-Total 71.39 86.04 61.67
Non-current Liabilities-Total 81.85 66.28 11.73
Total Liabilities 153.25 152.32 73.4
Stockholder's Equity
Share Capital 100 100 27.48
Retained Profits 83.09 4.6 16.8
Total Owners' Equity 651.68 563.76 451.7

Cash Flow Statement (Unit: RMB mn)

  2020 2019 2018
Net Cash Flows-Operating 84.88 88.45 79.73
Net Cash Flows-Investing -143.28 -206.5 -101.1
Net Cash Flows-Financing 4.23 107.23 94

Top 10 Shareholders

Name No. of Shares Held (mn) % of Shares Held
嘉兴华控股权投资基金合伙企业(有限合伙) 12.98 9.73%
北京奇伦天佑创业投资有限公司 12.09 9.07%
Bioveda china RMB Investment limited 11.76 8.82%
Eric Gang Hu 9.49 7.12%
北京银河九天信息咨询中心(有限合伙) 7.76 5.82%
上海百奥财富医疗投资合伙企业(有限合伙) 7.54 5.66
崔福斋 6.33 4.75
杭州创合精选创业投资合伙企业(有限合伙) 5.84 4.38
杭州镜心投资合伙企业(有限合伙) 4.31 3.23
As of 2021-05-21

Legal Statement

All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.

Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.

Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.